Bassler Bonnie L 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Nov 24, 2025
Insider Transaction Report
Form 4
Bassler Bonnie L
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-20$371.40/sh+760$282,264→ 2,308 total - Sale
Common Stock
2025-11-20$750.00/sh−760$570,000→ 1,548 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-20−760→ 756 totalExercise: $371.40Exp: 2029-01-02→ Common Stock (760 underlying)
Footnotes (2)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
- [F2]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.